Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis
British Journal of Dermatology · 17.10.2024 · 191 (5) · 719-727
DOI: 10.1093/bjd/ljae250 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Dermatology, online erschienen am 27.06.2024. Verfasst von Kristina Hagenström und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Glucocorticoids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Systemic glucocorticosteroids (SGCs) are used in the short-term treatment of atopic dermatitis (AD), but are not recommended for long-term use because they are associated with severe side-effects.
Objectives
This study aimed to characterize the utilization and potentially negative effects of SGC use for AD in German statutory health insurance (SHI) claims data.
Methods
Cross-sectional and longitudinal analysis of a large nationwide SHI dataset. SGC drug prescriptions and incidences of predefined comorbidities after drug initiation that were known to be potentially harmful side-effects were analysed. SGC use was quantified by (definition 1) the number of quarters with at least one SGC prescription and (definition 2) the defined daily doses (DDD). Comparisons were adjusted for age, sex and morbidity.
Results
The AD prevalence was 4.07% in 2020 (4.12% women, 3.42% men). During this period 9.91% of people with AD were prescribed SGCs compared with 5.54% in people without AD (P < 0.01). Prescribing of SGCs was significantly higher in women (10.20% vs. 9.42% in men, P < 0.01) and in the elderly. AD and SGC prevalence varied regionally. In a 3-year follow-up period, 58% of people with AD receiving a SGC were prescribed SGCs in > one quarter and 15% in > six quarters. The odds of developing osteoporosis [odds ratio (OR) 3.90 (definition 1) and 1.80 (definition 2)] and diabetes [OR 1.90 (definition 1) and 1.38 (definition 2)] were significantly higher in people with AD on SGCs, especially in the frequently prescribed group compared with the rarely prescribed group, regardless of quantified use.
Conclusions
A considerable number of people with AD in Germany are prescribed long-term SGCs. The onset of medical conditions known to be harmful effects of steroids was significantly more frequent in those who were frequently prescribed SGCs, indicating the need for optimized healthcare.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
ORCID-Profile: Matthias Augustin
Zitieren
APA
Hagenström, K., Klinger, T., Müller, K., Willers, C., & Augustin, M. (2024). Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis. British Journal of Dermatology, 191(5), 719-727. https://doi.org/10.1093/bjd/ljae250
Vancouver
Hagenström K, Klinger T, Müller K, Willers C, Augustin M. Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis. British Journal of Dermatology. 2024;191(5):719-727. doi:10.1093/bjd/ljae250
BibTeX
@article{Hagenstrm2024,
author = {Hagenström, Kristina and Klinger, Theresa and Müller, Katharina and Willers, Charlotte and Augustin, Matthias},
title = {Utilization and related harms of systemic glucocorticosteroids for atopic dermatitis: claims data analysis},
journal = {British Journal of Dermatology},
year = {2024},
volume = {191},
number = {5},
pages = {719--727},
doi = {10.1093/bjd/ljae250}
}
EUVIMED